The specter of generic rivalry has consistently loomed above copyright’s famous drug, PDE5 Inhibitor, raising questions about the prospects of similar drug investments. While first times saw significant gains, the patent lapse has created the door for less expensive alternatives, possibly diminishing earnings and creating a genuine danger for inv